医薬品リファレンス
Trastuzumab deruxtecan
Trastuzumab deruxtecan is a medicine in the class oncology. It is used for breast cancer.
- 薬効分類: Oncology
- 効能・効果: breast cancer
最終更新日 出典: US FDA label, EMA SmPC
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
要点
- 薬効分類
- Oncology
- ATCコード
- L01FD04
- 一般的な剤形
- 注射剤
- 一般的な規格
- 100 mg/5 ml
- 既知の相互作用
- 100 (重大: 16 · 中等度: 78 · 軽度: 6)
- 商品名
- 2
- 国・市場
- 2
何に使われるか
作用のしくみ
HER2-directed antibody-drug conjugate: a humanized anti-HER2 IgG1 linked by a cleavable linker to DXd, a topoisomerase I inhibitor. After binding HER2, it is internalized and the linker is cleaved by lysosomal enzymes; released DXd causes DNA damage and apoptotic cell death.
成人の通常用量（添付文書の要約）
HER2-positive, HER2-low or HER2-ultralow metastatic breast cancer, HER2-mutant NSCLC, HER2-positive (IHC 3+) solid tumors: 5.4 mg/kg IV infusion every 3 weeks as monotherapy until disease progression or unacceptable toxicity
妊娠と授乳
- 妊娠
- Unsafe Can cause fetal harm; HER2-directed antibodies linked to oligohydramnios, pulmonary hypoplasia, skeletal abnormalities and neonatal death. No human data.
- 授乳
- Unsafe No human milk data; advise not to breastfeed during treatment and for 7 months after last dose.
報告されている副作用
- Decreased white blood cell count
- Nausea
- Decreased hemoglobin
- Decreased neutrophil count
- Decreased lymphocyte count
- Fatigue
警告（枠囲み警告）
- Interstitial lung disease and pneumonitis, including severe, life-threatening and fatal cases, occur. Monitor for and investigate cough, dyspnea, fever and new respiratory symptoms. Permanently discontinue in all patients with Grade 2 or higher ILD/pneumonitis.
注意が必要な方
- ILD/pneumonitis: monitor, evaluate with imaging, give corticosteroids; withhold or permanently discontinue per grade.
- Neutropenia including febrile neutropenia: monitor CBC before initiation and before each dose.
- Left ventricular dysfunction: assess LVEF before initiation and at regular intervals; not studied with LVEF less than 50%.
妊娠中または授乳中であること、腎臓や肝臓の病気、アレルギー、ほかに使用しているすべての薬やサプリメントについて、薬剤師または医師にお伝えください。
主な相互作用 (100)
- Ado-trastuzumab + Trastuzumab deruxtecan Major
- Azathioprine + Trastuzumab deruxtecan Major
- Bleomycin + Trastuzumab deruxtecan Major
- Dacarbazine + Trastuzumab deruxtecan Major
- Daunorubicin + Trastuzumab deruxtecan Major
- Deferiprone + Trastuzumab deruxtecan Major
- Doxorubicin + Trastuzumab deruxtecan Major
- Epirubicin + Trastuzumab deruxtecan Major
- Idarubicin + Trastuzumab deruxtecan Major
- Irinotecan + Trastuzumab deruxtecan Major
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、Trastuzumab deruxtecanの完全なモノグラフ（用量、妊娠・授乳、副作用、警告、すべての相互作用）を表示できます。
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- How to give it
- Pharmacokinetics
- Patient counselling points
WebでPro+を14日間無料でお試し。カード登録不要。
同じ分類のほかの薬剤
よくある質問
What is Trastuzumab deruxtecan used for?
Trastuzumab deruxtecan is a medicine in the class oncology. It is used for Breast cancer, Gastric cancer, Non-small cell lung cancer.
What side effects have been reported with Trastuzumab deruxtecan?
Decreased white blood cell count, Nausea, Decreased hemoglobin, Decreased neutrophil count, Decreased lymphocyte count, Fatigue. Serious warning: Interstitial lung disease and pneumonitis, including severe, life-threatening and fatal cases, occur.
Can Trastuzumab deruxtecan be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm; HER2-directed antibodies linked to oligohydramnios, pulmonary hypoplasia, skeletal abnormalities and neonatal death. No human data. Breastfeeding: Unsafe. No human milk data; advise not to breastfeed during treatment and for 7 months after last dose.
What does Trastuzumab deruxtecan interact with?
MediHelp lists 100 known interactions for Trastuzumab deruxtecan. Major: 16 · Moderate: 78 · Minor: 6. The most serious include Ado-trastuzumab, Azathioprine, Bleomycin.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
